GOSS

Gossamer Bio (GOSS)

About Gossamer Bio (GOSS)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Details

Daily high

$1.06

Daily low

$1.01

Price at open

$1.05

52 Week High

$1.60

52 Week Low

$0.45

Market cap

230.8M

Dividend yield

0.00%

Volume

604,084

Avg. volume

992,030

P/E ratio

-2.55

Gossamer Bio News